Retatrutide and muscle loss: what the studies measured

Reviewed 11 sourcesPublished by PepVault

How much lean mass people lost on retatrutide in its DXA scan study, dose by dose, how it compares with tirzepatide and semaglutide, and what phase 3 left out.

Grey-haired man in a black tank sets up a barbell deadlift in a plant-filled garage gym
Last reviewed
Sources
11
Questions
6
Compounds
3

The short answer

Retatrutide takes some lean mass with the fat. In its one body-scan study, 36 weeks in type 2 diabetes, the 8 mg and 12 mg groups lost about 6.4 to 6.5 kg of lean mass beside 10.5 to 10.9 kg of fat: roughly 37 to 38% of the tissue lost was lean. That is the top of semaglutide's range (30 to 40%), above tirzepatide's quarter. No trial has measured strength.

Every number checked at its primary source · · 11 sources · How we research

Evidence: Human trials: one phase 2 DXA substudy of retatrutide in type 2 diabetes (36 weeks), read with two 2026 reviews of its results, DXA data from the phase 3 SURMOUNT-1 and STEP 1 trials for comparison, a human glucagon infusion study, the TRIUMPH registry records, and a 2025 joint advisory; retatrutide is investigational and not approved.

Grey-haired man in a black tank sets up a barbell deadlift in a plant-filled garage gym

How much lean mass did people lose on retatrutide?

The only measured answer so far comes from a substudy of Lilly's phase 2 trial in type 2 diabetes. At 42 US clinics, 189 adults were scanned with DXA, a low-dose X-ray that splits the body into fat, bone and lean mass (pepvault.app/glossary/lean-mass), and given a weekly shot of retatrutide (0.5, 4, 8 or 12 mg), dulaglutide 1.5 mg, an older GLP-1 drug, or placebo for 36 weeks1. Of the 189, 103 finished treatment with a scan at both ends1.

Fat came off fast at the higher doses: total fat mass fell 26.1% on 8 mg and 23.2% on 12 mg, against 4.5% on placebo and 2.6% on dulaglutide1. In kilograms, that was about 10.9 kg and 10.5 kg of fat, with about 6.5 kg and 6.4 kg of lean mass going with it2. A second review gives the same 6.5 kg of lean mass for the pooled 8 mg group, out of 16.8 kg of body weight, against 2.1 kg of weight on placebo3.

Group, 36 weeksFat mass changeLean share of the tissue lost
Retatrutide 0.5 mg-4.9%1About 16%2
Retatrutide 4 mg-15.2%1About 30%2
Retatrutide 8 mg-26.1%, about 10.9 kg12About 37% (6.5 kg lean)2
Retatrutide 12 mg-23.2%, about 10.5 kg12About 38% (6.4 kg lean)2
Dulaglutide 1.5 mg-2.6%1Not given in the sources
Placebo-4.5%1Not given in the sources

The fat percentages are the paper's own1. Its full text is not open to read, so the kilograms and lean shares are as two 2026 reviews report them from its results23. Lean mass on a scan is more than muscle: it also counts organs, water and stored carbohydrate, which is why the guide on muscle on a GLP-1 (pepvault.app/guides/muscle-on-a-glp-1) treats it as an upper bound. Our study page (pepvault.app/research/retatrutide-coskun-2025) tells the trial in plain words.

PepVault's Body page logs every weigh-in and a body check-in of waist, neck and hip, and estimates body fat from them with the US Navy formula, so the trend shows more than the scale. Track your weight in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Body page logs every weigh-in and a body check-in of waist, neck and hip, and estimates body fat from them with the US Navy formula, so the trend shows more than the scale.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does a higher retatrutide dose take more muscle?

In this one study, yes: the lean share climbed with the dose, from about 16% of the loss on 0.5 mg to about 30% on 4 mg and 37 to 38% on 8 and 12 mg2. The higher doses also took off far more fat, so the trade is more fat lost for a larger lean slice, not less fat.

The review that reports the pattern calls it hypothesis-generating: it does not show that a lower dose keeps muscle working better, or that it keeps the weight loss2. The groups were small, around 30 people each at entry, and only about half of the people who entered the substudy had both scans1. Which dose anyone takes is the prescriber's decision; the trial doses and steps are in our guide to retatrutide dosage in trials (pepvault.app/guides/retatrutide-dosage-in-trials).

Is retatrutide worse for muscle than tirzepatide or semaglutide?

By share, it sits at the top of semaglutide's range, above tirzepatide. In SURMOUNT-1's scan group, about 75% of the weight lost on tirzepatide was fat and 25% lean, the same split as placebo4. On semaglutide 2.4 mg in STEP 1, people lost 9.3 kg of fat and 5.8 kg of lean mass by week 685, so about 38% of the tissue lost was lean. Other semaglutide scans land between about 30% (the semaglutide arm of the BELIEVE trial) and 40% (STEP 1's published substudy and SUSTAIN 8)2. Retatrutide's 8 and 12 mg groups land at 37 to 38%2.

Trial and groupWho and how longLean share of the tissue lost
SURMOUNT-1, tirzepatide 5 to 15 mgObesity, no diabetes, 72 weeksAbout 25%4
STEP 1, semaglutide 2.4 mgObesity, no diabetes, 68 weeksAbout 38% (5.8 of 15.1 kg)5
Phase 2 substudy, retatrutide 8 mgType 2 diabetes, 36 weeksAbout 37%2
Phase 2 substudy, retatrutide 12 mgType 2 diabetes, 36 weeksAbout 38%2

The two readings of the same data differ. Lilly's authors conclude the lean share was similar to other obesity treatments, and that this could reassure that retatrutide does not take a larger proportion of lean mass despite the bigger weight loss1. The 2026 review reads the 38% as above the usual one-quarter estimate and close to semaglutide's upper range, and suggests the most potent drugs may take more lean mass in absolute and proportional terms2. Both can stand: the trials differ in people, diabetes and length, so no head-to-head verdict exists yet.

In kilograms the answer is clearer. More weight comes off on retatrutide, so more lean mass goes with it: 6.5 kg on 8 mg in 36 weeks23, against 5.6 kg on tirzepatide over 72 weeks in SURMOUNT-14.

Why would retatrutide's glucagon part matter for muscle?

Retatrutide works three receptors: GLP-1 and GIP, the two tirzepatide uses, plus glucagon (pepvault.app/glossary/glucagon). Glucagon tells the liver to make sugar, and it also draws amino acids, the building blocks of protein (pepvault.app/glossary/amino-acid), out of the blood and into the liver6. That is the reason muscle is the open question for a triple agonist.

In a Mayo Clinic study of 16 healthy people, a glucagon infusion with insulin held low at least doubled the exchange of amino acids between muscle and liver: more left the muscle and more went into the liver, and the muscle lost protein on balance, mostly because it built less, not because it broke down more6. Retatrutide's GLP-1 and GIP arms raise insulin, so that setting is not the drug's, and a 2026 review of retatrutide says its effects on blood amino acids and lean tissue still need direct study7.

What did the phase 3 trials measure about muscle?

Less than people expect. TRIUMPH-1, the first phase 3 obesity trial, gave 2,339 adults without diabetes retatrutide or placebo for 80 weeks; weight fell 25.0% on 12 mg against 3.9% on placebo8. Its registered outcomes include weight, waist, BMI and two physical-function questionnaires, but no body-composition scan9, and the published abstract does not report the questionnaires8. Our study page (pepvault.app/research/retatrutide-triumph-1-2026) tells the trial in plain words. TRIUMPH-5, the head-to-head trial against tirzepatide, registers no scan either10.

So the 36-week scan study in type 2 diabetes is still the only lean-mass data. Phase 3 losses run larger and longer than that study's, which makes the absolute lean loss at 80 weeks the number nobody has measured. For everything else the drug did in these trials, see our guides to retatrutide side effects (pepvault.app/guides/retatrutide-side-effects) and whether retatrutide is safe (pepvault.app/guides/is-retatrutide-safe).

How do people protect muscle on retatrutide?

No retatrutide trial has tested exercise or protein. The best evidence comes from the GLP-1 class: a 2025 advisory from four US obesity and nutrition societies pairs these drugs with strength training at least three times a week plus 150 minutes of moderate aerobic exercise, and lists 1.2 to 1.6 g of protein per kg a day as proposed during active weight loss11. Those are published ranges, not a prescription; the protein calculator (pepvault.app/tools/glp1-protein-calculator) works the range out for a given weight.

Commonly reported: protein being the hardest number to reach once appetite drops, eating the protein part of the meal first, and lifts holding steady in the gym while the scale keeps falling.

In PepVault, Food sets your daily protein target; on a weight-loss goal it is 1.6 g per kg of your goal weight while you are above it. Track your food in PepVault

When to get help If stairs, carrying shopping or getting up from a chair get harder while the weight comes off, raise it with your clinician.

Track it in the app

Sources

  1. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PubMed 40609566
  2. Kim JY, Kim NH. Beyond fat loss: addressing the sarcopenia challenge of incretin-based therapies. Diabetes Metab J. 2026;50(5):844-862. PubMed 42722378
  3. Imaizumi T, Yabe D. Beyond weight loss: preserving muscle health in the incretin era. J Diabetes Investig. 2026;17(10):1658-1661. PubMed 42576312
  4. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PubMed 39996356
  5. Novo Nordisk A/S. STEP 1: semaglutide 2.4 mg in people with overweight or obesity (NCT03548935). ClinicalTrials.gov results: body composition by DXA, baseline to week 68. clinicaltrials.gov
  6. James H, Gonsalves WI, Manjunatha S, et al. The effect of glucagon on protein catabolism during insulin deficiency: exchange of amino acids across skeletal muscle and the splanchnic bed. Diabetes. 2022;71(8):1636-1648. PubMed 35621914
  7. Mateescu DM, Capraru ID, Enache B, Enache A. Retatrutide as a unimolecular GIP/GLP-1/glucagon receptor tri-agonist: molecular design, pharmaceutical development and critical interpretation of emerging phase 3 evidence. Pharmaceutics. 2026;18(10):1277. PubMed 42942810
  8. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026;395(18):1781-1793. PubMed 42814954
  9. Eli Lilly and Company. TRIUMPH-1: retatrutide in participants who have obesity or overweight (NCT05929066). ClinicalTrials.gov record: registered outcomes. clinicaltrials.gov
  10. Eli Lilly and Company. TRIUMPH-5: retatrutide compared to tirzepatide in adults who have obesity (NCT06662383). ClinicalTrials.gov record: registered outcomes. clinicaltrials.gov
  11. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo